Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IXB-322
- Development stage
- Preclinical
- Lead developer
- iX Biopharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Sublingual
01
Overview
IXB-322 is a novel, low-dose interferon biologic developed by iX Biopharma for the prevention and treatment of respiratory viral infections, including COVID-19, influenza, and respiratory syncytial virus (RSV). The drug utilizes the proprietary WaferlogiX platform, a specialized version of the WaferiX sublingual delivery technology designed for biologics, to deliver interferon directly to the oral mucosa. This sublingual administration is intended to stimulate a localized and beneficial immune response while bypassing the harsh acidic and enzymatic environment of the gastrointestinal tract. By using a low-dose approach, IXB-322 aims to provide therapeutic efficacy against viral pathogens while avoiding the systemic toxicity and adverse side effects typically associated with high-dose interferon administrations.
- Other names
- low-dose interferon sublingual wafer
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on IXB-322.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IXB-322.